Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia.
about
Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cellsPTEN regulates BCRP/ABCG2 and the side population through the PI3K/Akt pathway in chronic myeloid leukemiaERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapyClonal competition in BcrAbl-driven leukemia: how transplantations can accelerate clonal conversion.Chronic myeloid leukemia: mechanisms of blastic transformationThe proteolytic activity of separase in BCR-ABL-positive cells is increased by imatinibOncogenic tyrosine kinases target Dok-1 for ubiquitin-mediated proteasomal degradation to promote cell transformationHigh levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiationReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia.Re-evaluating the role of BCR/ABL in chronic myelogenous leukemiaMolecular biology of bcr-abl1-positive chronic myeloid leukemia.Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasiaTyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.
P2860
Q24670609-8CB47AEA-18F4-48A7-BEB1-95B7B2729D23Q28540547-BBF1794E-80AC-48AF-92C9-E3B0F73B00C8Q33476874-4D55750A-A394-41EF-A5A7-DA798E152430Q33908547-D49293A7-018A-4878-88C2-CE13551A8C68Q33968037-09978F7A-980F-4310-8146-BE49896B0C0FQ34369606-7758FD17-129A-40A4-B3ED-D74F97505771Q35096609-A6F504A5-1E46-4EE0-8DC2-D108CFDC60EDQ35901685-F1E3129D-A916-4243-9CE8-439B95853EF1Q36585748-A0439682-0630-43C1-B20C-4D313B14D6EDQ36997520-BF81E4E4-AE5B-42FD-B97F-CEBB5500EEAEQ37283128-CA4FCED2-0E09-450D-9A4F-0C36522FA08EQ37320065-FF839A46-5BB0-4275-B02C-78CFE1B0F805Q37919976-70AE5154-CFC4-4CDD-9017-070DC75262F5Q38866390-7F2F5BCE-F9D7-40B0-ACC1-1E10DF7817B7Q40350288-8AA0D1CF-F246-4708-9C4A-DEFFE57B8AA1
P2860
Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Dose-dependent effects of Bcr- ...... s of chronic myeloid leukemia.
@en
type
label
Dose-dependent effects of Bcr- ...... s of chronic myeloid leukemia.
@en
prefLabel
Dose-dependent effects of Bcr- ...... s of chronic myeloid leukemia.
@en
P2093
P2860
P356
P1433
P1476
Dose-dependent effects of Bcr- ...... s of chronic myeloid leukemia.
@en
P2093
Beate Schultheis
David J Barnes
Junia V Melo
Simisade Adedeji
P2860
P2888
P304
P356
10.1038/SJ.ONC.1208796
P407
P577
2005-09-01T00:00:00Z
P5875
P6179
1006352776